دورية أكاديمية
Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial ; ENEngelskEnglishPleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial
| العنوان: | Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial ; ENEngelskEnglishPleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial |
|---|---|
| المؤلفون: | Krogvold, Lars, Mynarek, Ida Maria, Ponzi, Erica, Mørk, Freja Barrett, Hessel, Trine Witzner, Roald, Trine, Lindblom, Nina, Westman, Jacob, Barker, Peter, Hyöty, Heikki, Ludvigsson, Johnny, Hanssen, Kristian Folkvord, Johannesen, Jesper, Dahl-Jørgensen, Knut |
| المصدر: | 1078-8956. |
| بيانات النشر: | Nature Portfolio |
| سنة النشر: | 2023 |
| المجموعة: | Universitet i Oslo: Digitale utgivelser ved UiO (DUO) |
| الوصف: | Previous studies showed a low-grade enterovirus infection in the pancreatic islets of patients with newly diagnosed type 1 diabetes (T1D). In the Diabetes Virus Detection (DiViD) Intervention, a phase 2, placebo-controlled, randomized, parallel group, double-blind trial, 96 children and adolescents (aged 6–15 years) with new-onset T1D received antiviral treatment with pleconaril and ribavirin (n = 47) or placebo (n = 49) for 6 months, with the aim of preserving β cell function. The primary endpoint was the mean stimulated C-peptide area under the curve (AUC) 12 months after the initiation of treatment (less than 3 weeks after diagnosis) using a mixed linear model. The model used longitudinal log-transformed serum C-peptide AUCs at baseline, at 3 months, 6 months and 1 year. The primary endpoint was met with the serum C-peptide AUC being higher in the pleconaril and ribavirin treatment group compared to the placebo group at 12 months (average marginal effect = 0.057 in the linear mixed model; 95% confidence interval = 0.004–0.11, P = 0.037). The treatment was well tolerated. The results show that antiviral treatment may preserve residual insulin production in children and adolescent with new-onset T1D. This provides a rationale for further evaluating antiviral strategies in the prevention and treatment of T1D. European Union Drug Regulating Authorities Clinical Trials identifier: 2015-003350-41. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | Krogvold, Lars Mynarek, Ida Maria Ponzi, Erica Mørk, Freja Barrett Hessel, Trine Witzner Roald, Trine Lindblom, Nina Westman, Jacob Barker, Peter Hyöty, Heikki Ludvigsson, Johnny Hanssen, Kristian Folkvord Johannesen, Jesper Dahl-Jørgensen, Knut . Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial. Nature Medicine. 2023; http://hdl.handle.net/10852/105935Test; 2193894; info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Nature Medicine&rft.volume=&rft.spage=&rft.date=2023; Nature Medicine; https://doi.org/10.1038/s41591-023-02576-1Test |
| DOI: | 10.1038/s41591-023-02576-1 |
| الإتاحة: | https://doi.org/10.1038/s41591-023-02576-1Test http://hdl.handle.net/10852/105935Test |
| حقوق: | Attribution 4.0 International ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.8E1F515A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s41591-023-02576-1 |
|---|